Virax Biolabs income statement data for the quarter ended Mar 2026. This income statement covers 9 quarters of results from Mar 2022 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2022 | Sep2022 | Mar2023 | Sep2023 | Mar2024 | Sep2024 | Mar2025 | Sep2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|
| Additional items | |||||||||
| Shares Outstanding | 10,203.00 | 10,203.00 | 42,519.00 | 42,519.00 | 80,257.00 | 80,257.00 | 149,214.00 | 149,214.00 | 397,590.00 |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 10,203.00 | 10,203.00 | 42,519.00 | 42,519.00 | 80,257.00 | 80,257.00 | 149,214.00 | 149,214.00 | 397,590.00 |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 10,203.00 | 42,519.00 | 80,257.00 | 173,678.00 | 397,590.00 |